Satement of retraction: Development and evaluation of tripalmitin emulsomes for the treatment of experimental visceral leishmaniasis (Journal of Liposome Research, (2012), 22, 1, (62-71), 10.3109/08982104.2011.592495);Development and evaluation of tripalmitin emulsomes for the treatment of experimental visceral leishmaniasis

Journal of Liposome Research

Volumn 22, Issue 1, 2012, Pages 62-71

  Pal, Ajay ^a   Gupta, Swati ^a   Jaiswal, Anil ^b   Dube, Anuradha ^b   Vyas, Suresh P ^c  

^a ISF COLLEGE OF PHARMACY   (India)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

^c DR H S GOUR UNIVERSITY   (India)

Author keywords

amphotericin B; Macrophage; O palmitoyl mannan; targeting

Indexed keywords

AMPHOTERICIN B; TRIPALMITIN; TRIPALMITIN EMULSOME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG ACTIVITY; DRUG COATING; DRUG FORMULATION; DRUG STABILITY; IN VIVO STUDY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PARASITE LOAD; PRIORITY JOURNAL; SPLEEN; VISCERAL LEISHMANIASIS;

AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; LEISHMANIASIS, VISCERAL; MACROPHAGES; MALE; PARASITIC SENSITIVITY TESTS; PARTICLE SIZE; STRUCTURE-ACTIVITY RELATIONSHIP; TRIGLYCERIDES;

EID: 84863115477     PISSN: 08982104     EISSN: 15322394     Source Type: Journal    
DOI: 10.1080/08982104.2022.2034335     Document Type: Erratum

References (35)

1. Agrawal AK, Agrawal A, Pal A, Guru PY, Gupta CM. (2002). Superior chemotherapeutic efficacy of amphotericin B in tuftsin-bearing liposomes against Leishmania donovani infection in hamsters. J Drug Target, 10:1-5.
2. Ahmad I, Sarkar AK, Bachhawat BK. (1989). Design of liposomes to improve delivery of amphotericin B in the treatment of aspergillosis. J Mol Cell Biochem, 91: 85-90. (Pubitemid 20007135)
3. Alving CR, Weldon JS, Munnell JF, Hanson WL. (1984). Liposomes in leishmaniasis: The lysosome connection. In: Gregoriadis G, Poste G, Senior J, Trouet A, ed. Receptor mediated targeting of drugs. Vol. 82, New York and London: Plenum Press, 317-31.
4. Amselem S, Friedman D. (1997). Solid fat nanoemulsions. US Patent, 5662932.
5. Amselem S, Yogev A, Zawoznik E, Friedman D. (1994). Emulsomes, a novel drug delivery technology. Proceedings of the International Symposium on Controlled Release of Bioactive Materials 21:1368-9.
6. Dea-Ayuela MA, Rama-Iniguez S, Sanchez-Brunete JA, Torrado JJ, Alunda JM, Bolas-Fernandez F. (2004). Anti-leishmanial activity of a new formulation of amphotericin B. Trop Med Int Health, 9:981-90. (Pubitemid 39278999)
7. Dube A, Sharma P, Srivastava JK, Misra A, Naik S, Katiyar JC. (1998). Vaccination of langur monkeys (Presbytis entellus) against Leishmania donovani with autoclaved L. major plus BCG. Parasitology, 116:219-21. (Pubitemid 28129373)
8. Dube A, Singh N, Sundar S, Singh N. (2005). Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in-vitro and in-vivo experimental models. Parasitol Res, 96:216-23. (Pubitemid 40933669)
9. Dube A, Srivastava JK, Sharma P, Chaturvedi A, Katiyar JC, Naik S. (1999). Leishmania donovani: cellular and humoral immune responses in Indian langur monkeys, Presbytis entellus. Acta Trop, 73:37-48. (Pubitemid 29238110)
10. Espuelas MS, Legrand P, Loiseau PM, Bories C, Barratt G, Irache JM. (2002). In vitro antileishmanial activity of amphotericin B loaded in poly (epsilon-caprolactone) nanospheres. J Drug Target, 10:593-9. (Pubitemid 36124359)
11. Gupta S, Dube A, Vyas SP. (2007). Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis. J Drug Target, 15:437-44. (Pubitemid 47073059)
12. Gupta S, Vyas SP. (2007). Development and characterization of amphotericin B bearing emulsomes for passive and active macrophage targeting. J Drug Target, 15:206-17. (Pubitemid 46562633)
13. Kafetzis DA, Velissariou IM, Stabouli S, Mavrikou M, Delis D, Liapi G. (2005). Treatment of paediatric visceral leishmaniasis: Amphotericin B or pentavalent antimony compounds? Int J Antimicrob Agents, 25:26-30. (Pubitemid 40023342)
14. Khan MA, Nasti TH, Owais M. (2005). Incorporation of amphotericin B in tuftsin- bearing liposomes showed enhanced efficacy against systemic cryptococcosis in leucopenic mice. J Antimicrob Chemother, 56:726-31. (Pubitemid 41487775)
15. Kole L, Sarkar K, Mahato SB, Das PK. (1994). Neoglycoprotein conjugated liposomes as macrophage specific drug carrier in the therapy of leishmaniasis. Biochem Biophy Res Commun, 200:351-8. (Pubitemid 24183614)
16. Kretschmar M, Amselem S, Zawoznik E, Mosbach K, Dietz A, Hof H, Nichterlein T. (2001). Efficient treatment of murine systemic infection with Candida albicans using amphotericin B incorporated in nanosize range particles (emulsomes). Mycoses, 44:281-6.
17. Lopez-Berestein G, Mehta R, Hopffer R, Mills K, Kasi L, Mehta K, Fainstein V, Luna M, Harsh EN, Juliano R. (1983). Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome- encapsulated amphotericin B. J Infect Dis, 147:939-45. (Pubitemid 13094246)
18. Manandhar KD, Yadav TP, Prajapati VK, Kumar S, Rai M, Dube A, Srivastava ON, Sundar S. (2008). Antileishmanial activity of nano-amphotericin B deoxycholate. J Antimicrob Chemother, 62:376-80. (Pubitemid 351984784)
19. Mehta R, Lopez-Berestein G, Hopffer R, Mills K, Juliano RL. (1984). Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim Biophys Acta, 770:230-4. (Pubitemid 14165264)
20. Melby PC. (2002). Recent developments in leishmaniasis. Curr Opin Infect Dis, 15:485-90.
21. Mullen AB, Baillie AJ, Carter KC. (1998). Visceral leishmaniasis in the BALB/c Mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B. Antimicrob Agent Chemother, 42:2722-25. (Pubitemid 28462922)
22. Mullen AB, Carter KC, Baillie AJ. (1997). Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis. Antimicrob Agents Chemother, 41:2089-92. (Pubitemid 27422195)
23. New RRC. (1990). Introduction and preparation of liposomes. In: New RRC, ed. Liposomes: A practical approach. Oxford:IRL Press, 1-104.
24. Rex JH, Walsh TJ. (1999). Estimating the true cost of amphotericin B. Clin Infect Dis, 29:1408-10.
25. Rocheleau H, Saint-Germain G, Barwicz J, Gruda I, Therien HM. (1994). Modulation of amphotericin B activity by association with mannose ester. Immunopharmacol Immunotoxicol, 16:419-36. (Pubitemid 24285738)
26. Sanchez-Brunete JA, Dea MA, Rama S, Bolas F, Alunda JM, Raposo R, Mendez MT, Torrado-Santiago S, Torrado JJ. (2004). Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres. Antimicrob Agents Chemother, 48: 3246-52. (Pubitemid 39129314)
27. Sunamoto J, Gato M, Iida T, Hara K, Saito A, Tomonega A. (1985). Polymer coated liposomes for drug delivery to target specific organs. In: Gregoriadis G, Senior J, Trouet A, ed. Receptor mediated targeting of drugs. NewYork:PlenumPress, 359-71.
28. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray H. W. (2010). Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med, 362: 504-512.
29. Townsed RW, Zutshi A, Bekersky I. (2001). Biodistribution of 4-[(14)C] cholesterol-AmBisome following a single intravenous administration to rats. Drug Metab Dispos, 29: 681-5. (Pubitemid 32374569)
30. Venier-Julienne MC, Vouldoukis I, Monjour L, Benoit JP. (1995). In vitro study of the anti-leishmanial activity of biodegradable nanoparticles. J Drug Target, 3:23-9.
31. Venkatesan N, Vyas SP. (2000). Polysaccharide coated liposomes for oral immunization: Development and characterization. Int J Pharm, 203:169-77. (Pubitemid 30627637)
32. Vyas SP. (2000). Macrophage targeting and colloidal drug carriers. In: Vyas SP, Dixit VK, ed. Advances in liposomal research. New Delhi, India:CBS Publisher and Distributor, 98-120.
33. Vyas SP, Katare YK, Mishra V, Sihorkar V. (2000). Ligand directed macrophage targeting of amphotericin B loaded liposomes. Int J Pharm, 210:1-14. (Pubitemid 32332637)
34. Vyas SP, Khar RK. (2002). Drug delivery to bone marrow. In: Vyas SP, Khar RK, ed. Targeted and controlled drug delivery, novel carrier systems. New Delhi, India: CBS Publisher and Distributor, 562-85.
35. Vyas SP, Quraishi S, Gupta S, Jaganathan KS. (2005). Aerosolized liposome-based delivery of amphotericin B to alveolar macrophages. Int J Pharm, 296:12-25. (Pubitemid 40693368)